Ontology highlight
ABSTRACT:
PROVIDER: PRJEB36203 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR3813600.fastq.gz | Fastqsanger.gz | |||
| ERR3813610.fastq.gz | Fastqsanger.gz | |||
| ERR3813620.fastq.gz | Fastqsanger.gz | |||
| ERR3813630.fastq.gz | Fastqsanger.gz | |||
| ERR3813640.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 49 |
Similar Datasets
Project description:To further development of our gene expression approach in different groups of leprosy, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to distinguish leprosy reactions and relapse cases from healthy controls. Human biopsy and skin slit were collected from reaction cases, PB cases, MB cases, relapse cases and healthy contacts. Total 1891,1384, 1134, 475 and 762 no of genes were overexpressed in PB, T1R, T2R, LL and relapse cases respectively. Expression of seven genes (glcB, infB, ftsH, ppgk,relA, rpsR and atpB) from relapse cases was quantified in the same RNA samples by real-time PCR confirming role of theses genes in relapse cases.
2024-03-04 | GSE224736 | GEO
Project description:Individuals exposed to Mtb can experience a range of outcomes: early bacterial clearance, latent Mtb infection (LTBI), asymptomatic TB (bacteriologically confirmed or not), or symptomatic TB (bacteriologically confirmed or clinically diagnosed). Current tools cannot reliably predict or distinguish these stages. Previous studies have identified Mtb peptides in extracellular vesicles (EVs) from TB patients’ serum, highlighting their potential as biomarkers. We aimed to identify Mtb proteins and peptides in serum EVs as potential biomarkers across TB stages, with a focus on differentiating asymptomatic individuals. We evaluated multiple mass spectrometry approaches, including optimizing the liquid chromatography gradient (more hydrophobic), and iteratively removed dominant peptides, to identify and differentially quantify Mtb peptides. We analyzed serum samples from healthy, HIV-negative South African adult volunteers enrolled in a TB risk study. Samples were categorized as prevalent TB (diagnosed within 30 days of baseline), incident TB (collected at baseline from participants who later developed TB), activated TB (collected at diagnosis, during follow-up, from incident cases), or controls (collected at baseline from participants who did not develop TB within the 15 months of the study).
2026-03-03 | PXD068329 | Pride
Project description:Individuals exposed to Mtb can experience a range of outcomes: early bacterial clearance, latent Mtb infection (LTBI), asymptomatic TB (bacteriologically confirmed or not), or symptomatic TB (bacteriologically confirmed or clinically diagnosed). Current tools cannot reliably predict or distinguish these stages. Previous studies have identified Mtb peptides in extracellular vesicles (EVs) from TB patients’ serum, highlighting their potential as biomarkers. We aimed to identify Mtb proteins and peptides in serum EVs as potential biomarkers across TB stages, with a focus on differentiating asymptomatic individuals. We evaluated data-independent acquisition (DIA) mass spectrometry with different data analysis strategies to identify and differentially quantify Mtb peptides. We analyzed serum samples from healthy, HIV-negative South African adult volunteers enrolled in a TB risk study. Samples were categorized as prevalent TB (diagnosed within 30 days of baseline), incident TB (collected at baseline from participants who later developed TB), activated TB (collected at diagnosis, during follow-up, from incident cases), or controls (collected at baseline from participants who did not develop TB within the 15 months of the study).
2026-03-03 | PXD068195 | Pride
Project description:Individuals exposed to Mtb can experience a range of outcomes: early bacterial clearance, latent Mtb infection (LTBI), asymptomatic TB (bacteriologically confirmed or not), or symptomatic TB (bacteriologically confirmed or clinically diagnosed). Current tools cannot reliably predict or distinguish these stages. Previous studies have identified Mtb peptides in extracellular vesicles (EVs) from TB patients’ serum, highlighting their potential as biomarkers. We aimed to identify Mtb proteins and peptides in serum EVs as potential biomarkers across TB stages, with a focus on differentiating asymptomatic individuals. We evaluated data-independent acquisition (DIA) mass spectrometry with different data analysis strategies to identify and differentially quantify Mtb peptides. We analyzed serum samples from healthy, HIV-negative South African adult volunteers enrolled in a TB risk study. Samples were categorized as prevalent TB (diagnosed within 30 days of baseline), incident TB (collected at baseline from participants who later developed TB), activated TB (collected at diagnosis, during follow-up, from incident cases), or controls (collected at baseline from participants who did not develop TB within the 15 months of the study).
2026-03-03 | PXD068197 | Pride
Project description:Background: Pregnant and postpartum women are at high risk of developing active tuberculosis (TB), but transcriptional TB studies have excluded pregnant women. We identified differentially expressed genes (DEGs) in pregnant women who did and did not progress to active TB. Methods: We followed a cohort of pregnant Indian women with TB infection for one year postpartum, collecting blood at study entry, 6 weeks postpartum and active TB diagnosis. A prospective signature of risk was identified by comparing whole blood RNA sequencing data from women who developed active TB postpartum (cases) with those who remained healthy (controls). Results: We identified 9 cases and matched them to 18 controls by HIV status and gestational age. A gene set of risk was identified: Expression of KCNIP4 > 2.2 log CPM and S1PR4 < 7.3 log CPM indicated a high probability of developing active TB postpartum. SF3B4 (>4.3 log CPM) and PGAM1 (>6.6 log CPM) correctly classified postpartum cases and controls. Both pairs displayed high accuracy (AUC >0.9) and were unique from 36 published TB signatures.Conclusions: We identified two genes that prospectively differentiated pregnant women who developed active TB postpartum from those who did not. If validated, this signature could be useful in targeted TB prevention programs.
2021-09-01 | GSE168519 | GEO
Project description:In order to further improve our method for measuring gene expression after different days of schistosomiasis infection, we adopted whole-genome microarray expression analysis as the sequencing platform to identify those genes with potential for distinguishing different infection times (applicable for the corresponding exposure range of medical decisions in cases of schistosomiasis infection after different days). We infected 15-day, 24-day and 45-day healthy mice with schistosomiasis and determined a consensus characteristic of successful schistosomiasis infection, which could distinguish infection days and control samples. Through real-time PCR, the expression of genes with significant differential expression (such as DDAH1) in the same RNA samples was quantified, confirming the low-level expression after infection and the expected schistosomiasis infection response pattern.
2025-09-07 | GSE298216 | GEO
Project description:This dataset aims to dissect the whole blood transcriptional signature by determining if elements of the whole blood signature are still present in purified cell subpopulations. We aimed to characterise the transcriptional response during TB and identify if cell subsets drove changes in whole blood cellular composition. The aim of the experiment was to define transcriptional signatures in neutrophils, monocytes, CD4+ and CD8+ cells from blood of active TB patients and healthy controls to distinguish the signature of active TB patients from each other and from healthy controls. This will help in the diagnosis of active tuberculosis, which normally relies on culture of the bacilli, which can take up to 6 weeks, sometimes the bacilli cannot be obtained from sputum thus requiring invasive techniques obtaining bronchoalveolar lavage (BAL). In some cases the bacill cannot be grown from sputum or BAL.
2010-08-11 | GSE19443 | GEO
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
| 2533916 | ecrin-mdr-crc
Project description:Multiomics of faecal samples collected from individuals in families with multiple cases of type 1 diabetes mellitus (T1DM) over 3 or 4 months. Metagenomic and metatranscriptomic sequencing and metaproteomics were carried out, as well as whole human genome sequencing. Phenotypic data is available.
2017-10-19 | MSV000081630 | MassIVE
Project description:Multiomics of faecal samples collected from individuals in families with multiple cases of type 1 diabetes mellitus (T1DM) over 3 or 4 months. Metagenomic and metatranscriptomic sequencing and metaproteomics were carried out, as well as whole human genome sequencing. Phenotypic data is available.
2016-08-22 | PXD003791 | Pride